BRAEBURN PHARMACEUTICALS

627 Davis Dr Ste 200, Morrisville, North Carolina, United States

Clinical Trials

4 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

41.7%

Phase 3

33.3%

Phase 2

25.0%

Trial Status Distribution

Active, not recruiting

33.3%

Completed

66.7%

Clinical Trials

Trials sponsored by this organization (12)

Buprenorphine (CAM2038) in Subjects With a Recent History of Moderate to Severe Chronic Low Back Pain

Phase 3

Completed

interventional

Sep 20161,053 participants

Study to Evaluate D2 Receptor Occupancy Following Single Intravenous Administration of ATI-9242

Phase 1

Completed

interventional

Jun 20167 participants

Safety and Tolerability of Risperidone Implants

Phase 3

Completed

interventional

Apr 2016140 participants

Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid Dependence

Phase 3

Completed

interventional

Dec 2015428 participants

Long-Term Safety Study of Buprenorphine (CAM2038) in Adult Outpatients With Opioid Use Disorder

Phase 3

Completed

interventional

Nov 2015228 participants

Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant

Phase 2

Completed

interventional

Oct 201566 participants

A Multiple Dose Opioid Challenge Study

Phase 2

Completed

interventional

Oct 201547 participants

An Open-Label Multicenter Study Assessing the Long-Term Safety of a Once-Weekly and Once-Monthly, Long-Acting Subcutaneous Injection Depot of Buprenorphine (CAM2038) in Adult Outpatients with Opioid Use Disorder

Phase 1

Active, not recruiting

Sep 2015228 participants

Page 1 of 2

Approvals

No approval data available

News

No news articles found

Back to Organizations